Main Article Content
Abstract
The present study focuses on the formulation and characterization of transdermal patches for the controlled delivery of Fravotriptan, a selective 5-HT1B/1D receptor agonist used in the treatment of migraine. Due to its short half-life and extensive first-pass metabolism, the oral delivery of Fravotriptan often results in reduced bioavailability and frequent dosing. To overcome these limitations, transdermal drug delivery systems (TDDS) offer a promising alternative by maintaining sustained drug release, enhancing patient compliance, and minimizing systemic side effects.
In this research, transdermal patches were formulated using varying concentrations of hydrophilic (HPMC E15) and hydrophobic Ethyl cellulose and Eudragit RL100, EC) polymers through the solvent casting method. Polyethylene glycol 400 (PEG-400) was employed as a plasticizer to improve flexibility and mechanical strength. The prepared patches were subjected to various physicochemical evaluations, including thickness, weight uniformity, folding endurance, tensile strength, moisture content, moisture uptake, drug content uniformity, pH, and in vitro drug release studies using Franz diffusion cells.Among all the formulations, the optimized patch demonstrated uniform thickness, high folding endurance, suitable drug content, and sustained drug release up to 12 hours, following Higuchi kinetics, suggesting a diffusion-controlled release mechanism. The optimized patch also exhibited good physical stability during short-term storage conditions.
This study successfully demonstrates the potential of transdermal patches as an effective system for the controlled and sustained delivery of Fravotriptan, offering a patient-friendly approach for the management of migraine.
In this research, transdermal patches were formulated using varying concentrations of hydrophilic (HPMC E15) and hydrophobic Ethyl cellulose and Eudragit RL100, EC) polymers through the solvent casting method. Polyethylene glycol 400 (PEG-400) was employed as a plasticizer to improve flexibility and mechanical strength. The prepared patches were subjected to various physicochemical evaluations, including thickness, weight uniformity, folding endurance, tensile strength, moisture content, moisture uptake, drug content uniformity, pH, and in vitro drug release studies using Franz diffusion cells.Among all the formulations, the optimized patch demonstrated uniform thickness, high folding endurance, suitable drug content, and sustained drug release up to 12 hours, following Higuchi kinetics, suggesting a diffusion-controlled release mechanism. The optimized patch also exhibited good physical stability during short-term storage conditions.
This study successfully demonstrates the potential of transdermal patches as an effective system for the controlled and sustained delivery of Fravotriptan, offering a patient-friendly approach for the management of migraine.
Keywords
Fravotriptan, migraine, transdermal patches, controlled release, HPMC, Eudragit RL100 and Ethyl cellulose.
Article Details
References
- 1. Audumbar Digambar Mali, Ritesh Bathe and Manojkumar Patil. An updated review on transdermal drug delivery systems. International Journal of Advances in Scientific Research 2015; 1(06): 244-254.
- 2. Shaila L, Pandey S and Udupa N. Design and Evaluation of Matrix Type Membrane Controlled Transdermal Drug Delivery System of Nicotin Suitable for Use in Smoking Cessation. Indian Journ. Pharm. Sci. 2006;68: 179-184.
- 3. Aarti N, Louk A.R.M.P, Russsel.O.P and Richard H.G. Mechanism of Oleic Acid Induced Skin Permeation Enhancement in Vivo in Humans. Jour. Control. Release. 1995; 37: 299-306.
- 4. Brown M.B and Jones S.A. Hyaluronic Acid: A Unique Topical Vehicle for Localized Drug Delivery of Drugs to the Skin. Jedv 2000; 19: 308-318.
- 5. Tsai J.C, Guy R.H, Thornfeldt C.R, Gaow.N, Feingold K.R and Elias P.M. Metabolic Approaches to Enchance Transdermal Drug Delivery. Jour. Pharm. Sci. 1998; 85:643-648.
- 6. Berner B and John V.A. Pharmacokinetic Characterization of Transdermal Delivery Systems. Jour. Clinical Pharmacokinetics. 1994; 26 (2): 121-34.
- 7. Baker W and Heller J. Material Selection for Transdermal Delivery Systems. In Transdermal Drug Delivery: Developmental Issues and Research Initiatives, J.Hadgraft and R.H.Guys, Eds. Marcel Dekker, Inc.,New York. 1989 Pp. 293-311.
- 8. Yamamoto T, Katakabe K, Akiyoshi K, Kan K and Asano T. Topical Application of Glibenclamide Lowers Blood Glucose Levels in Rats. Diabetes Res. Clin. Pract. 1990; 8: 19-22.
- 9. Rhaghuram Rk, Muttalik S, Reddy S. Once – Daily Sustained- Release Matrix Tablets of Nicorandil: Formulation and Invitro Evaluation. Aaps Pharm.Scitech. 2003; 4(4):480–488.
- 10. Shaila L, Pandey S, Udupa N. Design and Evaluation of Matrix Type Membrane Controlled Transdermal Drug Delivery System of Nicotin Suitable for Use in Smoking Cessation. Indian Journal of Pharmaceutical Sciences. 2006; 68:179-184.